Approval · Notice of Compliance 15827 · 2014
ACT RANITIDINE: Notice of Compliance 15827
Issued July 15, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15827
- Date
- July 15, 2014
- Company
- Actavis Pharma CompanyToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Manufacturer and product name change
- Therapeutic class
- Histamine H2-receeptor antagonist
- Canadian reference product
- ZANTAC
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACT RANITIDINE | 02248570 | Cancelled Post Market |
| ACT RANITIDINE | 02248571 | Cancelled Post Market |
Medicinal ingredients
- RANITIDINE HCL 150 MG per TAB
- RANITIDINE HCL 300 MG per TAB